Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NYSE MKT | Common Stock
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
In addition, the company develops commercial predictive biomarker blood test kit for A3AR.
It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.
The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 28, 24 | -1.49 Decreased by -34.20% | -0.26 Decreased by -473.08% |
| Nov 30, 23 | -0.44 Increased by +51.11% | -0.44 |
| Aug 31, 23 | -0.42 Increased by +47.50% | -0.42 |
| Jun 1, 23 | -0.65 Increased by +27.78% | -1.52 Increased by +57.24% |
| Mar 23, 23 | -1.11 Increased by +62.99% | -0.09 Decreased by -1.18 K% |
| Nov 25, 22 | -0.90 Increased by +52.63% | -1.10 Increased by +18.18% |
| Aug 25, 22 | -0.80 Increased by +57.89% | -1.05 Increased by +23.81% |
| May 26, 22 | -0.90 Increased by +25.00% | -1.40 Increased by +35.71% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 158.00 K Decreased by -19.39% | -1.98 M Increased by +22.41% | Decreased by -1.25 K% Increased by +3.75% |
| Dec 31, 23 | 158.00 K Decreased by -19.80% | -1.98 M Increased by +34.47% | Decreased by -1.25 K% Increased by +18.29% |
| Sep 30, 23 | 196.00 K Decreased by -3.92% | -1.76 M Increased by +30.33% | Decreased by -898.98% Increased by +27.48% |
| Jun 30, 23 | 196.00 K Decreased by -3.92% | -1.67 M Increased by +23.78% | Decreased by -852.04% Increased by +20.67% |
| Mar 31, 23 | 196.00 K Decreased by -4.39% | -2.55 M Decreased by -2.08% | Decreased by -1.30 K% Decreased by -6.77% |
| Dec 31, 22 | 197.00 K Decreased by -3.90% | -3.02 M Decreased by -24.03% | Decreased by -1.53 K% Decreased by -29.07% |
| Sep 30, 22 | 204.00 K Decreased by -18.73% | -2.53 M Increased by +25.62% | Decreased by -1.24 K% Increased by +8.48% |
| Jun 30, 22 | 204.00 K Decreased by -18.40% | -2.19 M Increased by +31.94% | Decreased by -1.07 K% Increased by +16.59% |